Research programme: antiangiogenic therapeutics- Exonate

Drug Profile

Research programme: antiangiogenic therapeutics- Exonate

Alternative Names: Serine/threonine-protein kinase 1 inhibitors; SPHINXes; SRPK1 inhibitors

Latest Information Update: 10 Feb 2017

Price : $50

At a glance

  • Originator Exonate
  • Class Small molecules
  • Mechanism of Action Cyclin-dependent kinase-activating kinase inhibitors; Vascular endothelial growth factors inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Wet age-related macular degeneration

Most Recent Events

  • 06 Feb 2017 Exonate announces intention to submit an application to regulatory authorities for clinical evaluation for Wet age-related macular degeneration
  • 06 Feb 2017 Exonate plans clinical trials for Wet age-related macular degeneration in early 2020
  • 06 Feb 2017 Exonate plans preclinical toxicology and safety studies for Wet age-related macular degeneration in United Kingdom
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top